NCT00420199 - A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

August 31, 2009

Study Completion Date

May 31, 2010

Conditions

Active Rheumatoid Arthritis

Interventions

DRUG

Abatacept

Vials (250 mg/vial), intravenous (IV), 10 mg/kg, monthly infusion , 12 months of treatment

DRUG

Placebo

Intravenous (IV) bags, IV, 0 mg, monthly infusion, 12 months of treatment

Trial Locations (10)

Local Institution, Brussels

Local Institution, Yvoir

Local Institution, Berlin

Local Institution, Berlin

Local Institution, Amsterdam

Local Institution, Barcelona

Local Institution, Barcelona

Local Institution, Stockholm

Local Institution, London

Local Institution, Leeds